Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 10/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | LIFR | P42702 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16448972 | 0.88 | GHSR (0.58) | GHSRNR1H4POLBHPGDTP53 | |
| SCHEMBL6069682 | 0.86 | MAPT (0.48) | POLBHPGDTP53ALDH1A1MAPT | |
| SCHEMBL1180047 | 0.82 | GHSR (0.45) | GHSRNR1H4ALDH1A1MAPTGPBAR1 | |
| SCHEMBL2003480 | 0.79 | NR1H4 (0.45) | NR1H4 | |
| SCHEMBL1999960 | 0.77 | NR1H4 (0.42) | NR1H4 | |
| SCHEMBL7080536 | 0.74 | ALDH1A1 (0.49) | POLBHPGDTP53ALDH1A1MAPT | |
| SCHEMBL7056273 | 0.73 | CYP2C9 (0.50) | HPGDTP53ALDH1A1MAPTKDM4E | |
| SCHEMBL3999218 | 0.73 | POLB (0.70) | GHSRNR1H4POLBALDH1A1MAPT | |
| SCHEMBL16009163 | 0.73 | ALDH1A1 (0.42) | POLBHPGDTP53ALDH1A1MAPT | |
| SCHEMBL16448979 | 0.73 | TSHR (0.66) | POLBHPGDTP53ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| US-10899723-B2 | Heterocyclic containing cyclopropyl FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-01-26 | — | — | US | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| WO-2018075207-A1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS, INC. (VG) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899723-B2 | Heterocyclic containing cyclopropyl FXR modulators | NR1H4, FXR1, GPBAR1 | GHSR 379/4885NR1H4 1/4885POLB 3969/4885 |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | NR1H4, FXR1, NR1H2 | GHSR 293/4885NR1H4 1/4885POLB 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.